Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder

Journal of Microencapsulation

Volumn 32, Issue 1, 2015, Pages 54-60

  Bari, Abdul ^a   Chella, Naveen ^b   Sanka, Krishna ^a   Shastri, Nalini R ^b   Diwan, Prakash V ^a  

^a Lalitha College of Pharmacy   (India)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Aerosil 200; BCS class II; Diabetes mellitus; Glibenclamide; in vivo efficacy; Poorly soluble; Self nanoemulsifying powder

Indexed keywords

COTTON SEED OIL; CREMOPHOR; GLIBENCLAMIDE; GLUCOSE; MIGLYOL; MYRISTIC ACID ISOPROPYL ESTER; OLEIC ACID; POLYSORBATE 80; PROPYLENE GLYCOL; SORBITAN OLEATE; SOYBEAN OIL; SUNFLOWER OIL; SURFACTANT; ANTIDIABETIC AGENT; EMULSION; GLUCOSE BLOOD LEVEL; NANOPARTICLE; POWDER;

ANGLE OF REPOSE; ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; IN VITRO STUDY; IN VIVO STUDY; IONIC STRENGTH; MALE; NANOEMULSION; NEW ZEALAND RABBIT; NONHUMAN; PARTICLE SIZE; POWDER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCANNING ELECTRON MICROSCOPY; SELF NANO EMULSIFYING POWDER; SURFACE AREA; X RAY POWDER DIFFRACTION; ANIMAL; CHEMISTRY; GLUCOSE BLOOD LEVEL; METABOLISM; ORAL DRUG ADMINISTRATION; RABBIT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; EMULSIONS; GLYBURIDE; HYPOGLYCEMIC AGENTS; NANOPARTICLES; POWDERS; RABBITS;

EID: 84936756097     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2014.944950     Document Type: Article

References (23)

1. Agarwal V, Siddiqui A, Ali H, Nazzal S. Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int J Pharm, 2009;366:44-52.
2. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy. Int J Pharm, 2006; 320:53-7.
3. Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P, Valizadeh H, Barzegar-Jalali M. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J Pharm Pharm Sci, 2005;8:175-81.
4. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm, 2007;329:166-72.
5. Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm, 2010;67:283-90.
6. Elbary AA, Salem HF, Maher ME. In vitro and in vivo evaluation of glibenclamide using surface solid dispersion (SSD) approach. British J Pharmacol Toxicol, 2011;2:51-62.
7. Esclusa-Dáza MT, Torres-Labandeira JJ, Katab M, Vila-Jatoa JL. Inclusion complexation of glibenclamide with 2-hydroxypropylb-cyclodextrin in solution and in solid state. Eur J Pharm Sci, 1994; 1:291-96.
8. Ford JL, Mann TE. Fast-Scan DSC and its role in pharmaceutical physical form characterisation and selection. Adv Drug Deliv Rev, 2012;64: 422-30.
9. Galal S, EL-Massik M, Abdallah O, Daabis N. Formulation of fast release glibenclamide liquid and semi-solid matrix filled capsules. Acta Pharm, 2003;53:57-64.
10. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm, 2007;341:26-34.
11. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 2001;212:233-46.
12. Malcolmson C, Satra C, Kantaria S, Sidhu A, Lawrence MJ. Effect of oil on the level of solubilization of testosterone propionate into non-ionic oil-in-water microemulsions. J Pharm Sci, 1998;87:109-16.
13. Mu H, Holm R, Mullertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm, 2013;453: 215-24.
14. Nazzal S, Smalyukh, II, Lavrentovich OD, Khan MA. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: Mechanism and progress of emulsion formation. Int J Pharm, 2002;235:247-65.
15. Nipun TS, Islam SMA. SEDDS of gliclazide: Preparation and characterization by in-vitro, ex-vivo and in-vivo techniques. Saudi Pharm J, 2013; DOI: 10.1016/j.jsps.2013.06.001 (in press).
16. Nnamani PO, Attama AA, Ibezim EC, Adikwu MU. SRMS142-based solid lipid microparticles:application in oral delivery of glibenclamide to diabetic rats. Eur J Pharm Biopharm, 2010;76:68-74.
17. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev, 2008;60:673-91.
18. Pouton CW. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci, 2000;11(Suppl 2):S93-8.
19. Serrano-Martin X, Payares G, Mendoza-Leon A. Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother, 2006;50:4214-6.
20. Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm, 1998;166:177-88.
21. Staniforth J. 2002. Powder flow. In: Aulton ME, ed. Pharmaceutics: The science of dosage form design. 2nd ed. NY: Churchill Livingstone, pp. 187-98.
22. Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res, 1994; 11:1132-42.
23. Warisnoicharoen W, Lansley AB, Lawrence MJ. Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour. Int J Pharm, 2000;198:7-27.